Literature DB >> 16001433

Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics.

Friedrich W Cremer1, Jelena Bila, Isabelle Buck, Mutlu Kartal, Dirk Hose, Carina Ittrich, Axel Benner, Marc S Raab, Ann-Cathrin Theil, Marion Moos, Hartmut Goldschmidt, Claus R Bartram, Anna Jauch.   

Abstract

To delineate multiple myeloma (MM) subgroups and their clonal evolution, we analyzed 81 newly diagnosed patients by interphase fluorescence in situ hybridization using a comprehensive probe set for 10 chromosomes and two IGH rearrangements. A median of 5 probes per patient displayed aberrant signal numbers (range, 1-10). Additional copies most frequently found were for 15q22, 19q13, 9q34, 11q23, and 1q21. Losses commonly observed were of 13q14.3, 17p13, and 22q11. Predominance of gain or loss was quantified by a copy number score (CS) for each patient. Two peaks (CS = +3 and CS = 0) were found by plotting patient copy number scores over CS values corresponding to hyperdiploid and nonhyperdiploid MM. Cluster analysis revealed four major branches: (i) gain of 9q, 15q, 19q, and/or 11q; (ii) deletion of 13q and t(4;14); (iii) t(11;14); and (iv) gain of 1q. Statistical modeling of an oncogenetic tree indicated that early independent events were gain of 15q/9q and/or 11q, t(11;14); deletion of 13q followed by t(4;14); and gain of 1q. Aberrations of 17p13, 22q11, 8p12, and 6q21 were found as subsequent events. MM with gain of 1q was delineated as a subentity with significantly higher beta-2-microglobulin and lower hemoglobin levels, indicating a poor prognosis. From our results, we propose a model of MM for clonal evolution.

Entities:  

Mesh:

Year:  2005        PMID: 16001433     DOI: 10.1002/gcc.20231

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  31 in total

1.  The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance.

Authors:  Fiona M Ross; Laura Chiecchio; GianPaolo Dagrada; Rebecca K M Protheroe; David M Stockley; Christine J Harrison; Nicholas C P Cross; Alex J Szubert; Mark T Drayson; Gareth J Morgan
Journal:  Haematologica       Date:  2010-04-21       Impact factor: 9.941

2.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

Review 3.  Microarray-based understanding of normal and malignant plasma cells.

Authors:  John De Vos; Dirk Hose; Thierry Rème; Karin Tarte; Jérôme Moreaux; Karéne Mahtouk; Michel Jourdan; Hartmut Goldschmidt; Jean-François Rossi; Friedrich W Cremer; Bernard Klein
Journal:  Immunol Rev       Date:  2006-04       Impact factor: 12.988

4.  In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.

Authors:  Erming Tian; Jeffrey R Sawyer; Christoph J Heuck; Qing Zhang; Frits van Rhee; Bart Barlogie; Joshua Epstein
Journal:  Genes Chromosomes Cancer       Date:  2014-03-17       Impact factor: 5.006

Review 5.  Latest advances and current challenges in the treatment of multiple myeloma.

Authors:  Anuj Mahindra; Jacob Laubach; Noopur Raje; Nikhil Munshi; Paul G Richardson; Kenneth Anderson
Journal:  Nat Rev Clin Oncol       Date:  2012-02-21       Impact factor: 66.675

6.  Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma.

Authors:  Alboukadel Kassambara; Dirk Hose; Jérôme Moreaux; Brian A Walker; Alexei Protopopov; Thierry Reme; Franck Pellestor; Véronique Pantesco; Anna Jauch; Gareth Morgan; Hartmut Goldschmidt; Bernard Klein
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

7.  Amplification of 1q21 and other abnormalities in multiple myeloma patients from a tertiary hospital in singapore.

Authors:  Alvin S T Lim; Sathish Krishnan; Tse Hui Lim; Karen See; Yit Jun Ng; Yu Min Tan; Natasha Choo; Lai Ching Lau; Sim Leng Tien; Jun Ma; Daryl Tan
Journal:  Indian J Hematol Blood Transfus       Date:  2013-09-04       Impact factor: 0.900

8.  Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma.

Authors:  Matthieu Schoenhals; Alboukadel Kassambara; Jean-Luc Veyrune; Jerome Moreaux; Hartmut Goldschmidt; Dirk Hose; Bernard Klein
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

9.  Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.

Authors:  A Seckinger; T Meissner; J Moreaux; H Goldschmidt; G M Fuhler; A Benner; M Hundemer; T Rème; J D Shaughnessy; B Barlogie; U Bertsch; J Hillengass; A D Ho; V Pantesco; A Jauch; J De Vos; J F Rossi; T Möhler; B Klein; D Hose
Journal:  Oncogene       Date:  2009-08-31       Impact factor: 9.867

10.  Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors.

Authors:  Carol Sweeney; Kenneth M Boucher; Wade S Samowitz; Roger K Wolff; Hans Albertsen; Karen Curtin; Bette J Caan; Martha L Slattery
Journal:  Genes Chromosomes Cancer       Date:  2009-01       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.